

05/6

DIALOG(R) File 351:Derwent WPI  
(c) 2001 Derwent Info Ltd. All rts. reserv.

009565130

WPI Acc No: 1993-258678/199332

XRAM Acc No: C93-114921

New von Willebrand factor antagonist fusion proteins - comprising  
antagonist fragment linked to stabilising protein, useful as  
antithrombotic agents

Patent Assignee: RHONE-POULENC RORER SA (RHON )

Inventor: FLEER R; FOURNIER A; GUITTON J; JUNG G; YEH P

Number of Countries: 022 Number of Patents: 006

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9315200	A1	19930805	WO 93FR87	A	19930128	199332 B
FR 2686901	A1	19930806	FR 921066	A	19920131	199344
FI 9403565	A	19940729	WO 93FR87	A	19930128	199437
			FI 943565	A	19940729	
NO 9402840	A	19940929	WO 93FR87	A	19930128	199444
			NO 942840	A	19940729	
EP 625199	A1	19941123	EP 93904131	A	19930128	199445
			WO 93FR87	A	19930128	
JP 7503369	W	19950413	JP 93512988	A	19930128	199523
			WO 93FR87	A	19930128	

Priority Applications (No Type Date): FR 921066 A 19920131

Cited Patents: 2.Jnl.Ref; EP 255206; EP 41362; WO 9113093; WO 9206999; WO  
9217192; WO 9300357

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9315200 A1 F 48 C12N-015/12

Designated States (National): CA FI JP NO US

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LU MC NL  
PT SE

FR 2686901 A1 36 C12P-021/02

EP 625199 A1 F C12N-015/12 Based on patent WO 9315200

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU NL  
PT SE

JP 7503369 W C12N-015/09 Based on patent WO 9315200

FI 9403565 A C12N-000/00

NO 9402840 A C12N-015/62

Abstract (Basic): WO 9315200 A

New recombinant polypeptides comprise: (a) an adhesive portion  
derived from the structure of von Willebrand's factor (vWF) and capable  
of at least partially antagonising the binding of vWF to platelets  
and/or subendothelium, and (b) a portion permitting the stabilisation  
and presentation of (a) in vivo.

Also claimed are: (1) a nucleotide sequence coding for (I); (2) an  
expression cassette comprising sequence (1) under the control of a  
transcription initiation region and opt. a transcription termination  
region; (3) a self-replicating plasmid contg. cassette (2); and (4) a  
recombinant eukaryotic or prokaryotic cell contg. sequence (1),  
cassette (2) or plasmid (3).

USE/ADVANTAGE - (I) are platelet aggregation inhibitors, some with  
higher activity than RG12986 (Bio Tech., 10, 66, 1992) and some being

} effective in the absence of botrocetin-type cofactors. They are esp.  
useful for treatment or prophylaxis of thrombosis.

Dwg.0/9

Title Terms: NEW; FACTOR; ANTAGONIST; FUSE; PROTEIN; COMPRISE; ANTAGONIST;  
FRAGMENT; LINK; STABILISED; PROTEIN; USEFUL; ANTITHROMBOTIC; AGENT

Derwent Class: B04; D16

International Patent Class (Main): C12N-015/09; C12N-015/12; C12N-015/62;  
C12P-021/02

International Patent Class (Additional): A61K-037/02; A61K-038/43;  
C07K-013/00; C07K-019/00; C12N-001/19; C12N-005/10; C12N-015/14;  
C12N-015/81

File Segment: CPI